Serpinopathies and the conformational dementias

Nature Reviews Genetics

Volumn 3, Issue 10, 2002, Pages 759-768

  Lomas, David A ^a   Carrell, Robin W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CHAPERONE; DOPAMINE; HUNTINGTIN; POLYMER; PRION PROTEIN; SERINE PROTEINASE INHIBITOR; TAU PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; AMYLOIDOSIS; BRAIN DISEASE; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DRUG DESIGN; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; PARKINSON DISEASE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; REVIEW;

AMYLOID; ANIMALS; DEMENTIA; DRUG DESIGN; HUMANS; INCLUSION BODIES; MODELS, MOLECULAR; MUTATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROPEPTIDES; NUCLEAR PROTEINS; PRIONS; PROTEIN CONFORMATION; SERPINS;

EID: 0036789017     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg907     Document Type: Review

References (100)

1. Carrell, R. W. & Lomas, D. A. Conformational diseases. Lancet 350, 134-138 (1997).
2. Kopito, R. R. & Ron, D. Conformational disease. Nature Cell Biol. 2, E207-E209 (2000).
3. Carrell, R. W. & Lomas, D. A. α-antitrypsin deficiency: a model for canformational diseases. N. Engl. J. Med. 346, 45-53 (2002).
4. Tran, P. B. & Miller, R. J. Aggregates in neurodegenerative disease: crowds and power? Trends Neurosci. 22, 194-197 (1999).
5. Walker, L. C. & LeVine, H. 3rd. The cerebral proteopathies. Neurobiol. Aging 21, 559-561 (2000).
6. Huntington, J. A., Read, R. J. & Carrell, R. W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923-926 (2000). The long-sought-after structure of the final complex of a serpin with its target proteinase.
7. Mast, A. E., Enghild, J. J., Pizzo, S. V. & Salvesen, G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of α-proteinase inhibitor, α-antichymotrypsin, antithrombin III, α-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 30, 1729-1730 (1991).
8. 1-antitrypsin accumulates in the liver by loop-sheet polymerization.
9. Stein, P. E. & Carrell, R. W. What do dysfunctional serpins tell us about molecular mobility and disease? Nature Struct. Biol. 2, 96-113 (1995).
10. 1-antitrypsin.
11. Brantly, M., Nukiwa, T. & Crystal, R. G. Molecular basis of α1-antitrypsin deficiency. Am. J. Med. 84 (Suppl. 6A), 13-31 (1988).
12. 1-Antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys. Clin. Genet. 60, 31-41 (2001).
13. Sharp, H. L., Bridges, R. A., Krivit, W. & Freier, E. F. Cirrhosis associated with α1-antitrypsin deficiency: a previously unrecognised inherited disorder. J. Lab. Clin. Med. 73, 934-939 (1969).
14. 1-antitrypsin deficient children. Acta Paediatr. Scand. 77, 847-851 (1988).
15. 1-antitrypsin deficiency. N. Engl. J. Med. 314, 736-739 (1986).
16. 1-antitrypsin. Nature 298, 329-334 (1982).
17. 1-antitrypsin deficiency, PiZ. Acta Med. Scand. 204, 345-351 (1978).
18. 1-antitrypsin polymers.
19. 1-antitrypsin. Biochemistry 32, 500-508 (1993).
20. 1-antichymotrypsin indicates two stage insertion of the reactive loop; implications for inhibitory function and conformational disease. Proc. Natl Acad. Sci. USA 97, 67-72 (2000).
21. Mahadeva, R., Dafforn, T. R., Carrell, R. W. & Lomas, D. A. Six-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerisation: implications for the prevention of Z a-antitrypsin related cirrhosis. J. Biol. Chem. 277, 6771-6774 (2002).]
22. 1-antitrypsin polymers are formed by reactive loop-β-sheet A linkage. J. Biol. Chem. 275, 33663-33668 (2000).
23. 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP. J. Biol. Chem. 265, 20463-20468 (1990).
24. Janciauskiene, S., Dominaitiene, R., Sternby, N. H., Piitulainen, E. & Eriksson, S. Detection of circulating and endothelial cell polymers of Z and wildtype α1-antitrypsin by a monoclonal antibody. J. Biol. Chem. 277, 26540-26546 (2002).
25. 1-antitrypsin. J. Biol. Chem. 274, 9548-9555 (1999).
26. Skinner, R. et al. Implications for function and therapy of a 2.9Å structure of binary-complexed antithrombin. J. Mol. Biol. 283, 9-14 (1998).
27. Le, A., Ferrell, G. A., Dishon, D. S., Quyen-Quyen, A. L. & Sifers, R. N. Soluble aggregates of the human PiZ α- antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis. J. Biol. Chem. 287, 1072-1080 (1992).
28. 1-antitrypsin deficiency variants. J. Biol. Chem. 270, 8393-8396 (1995).
29. 1-antitrypsin-related liver disease (as opposed to those with plasma deficiency) have a lag in degrading the retained protein, which indicates that the handling of the polymers is likely to be important in determining which patients develop juvenile cirrhosis.
30. 1-antitrypsin retained in hepatocytes.
31. Bruce, D., Perry, D. J., Borg, J.-Y., Carrell, R. W. & Wardell, M. R. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen VI (187 Asn→Asp). J. Clin. Invest. 94, 2265-2274 (1994).
32. Beauchamp, N. J. et al. Antithrombins wibble and wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis and heparin activation. Blood 92, 2696-2706 (1998).
33. Zhou, A., Huntington, J. A. & Carrell, R. W. Formation of the antithrombin heterodimer and the onset of thrombosis. Blood 94, 3388-3396 (1999).
34. Corral, J. at al. Molecular characterization of the first homozygous heparin co-factor II deficiency. Involvement in conformational disease. Thrombosis Haemostasis (Suppl.) (2001).
35. Levashina, E. A. et al. Constitutive activation of toll-mediated antifungal defense in serpin-deficient Drosophila. Science 285, 1917-1919 (1999).
36. Seyama, K. et al. Siiyama(serine 53 (TCC) tophenylaianine 53 (TTC)). A new α1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J. Biol Chem. 266, 12627-12632 (1991).
37. Roberts, E. A., Cox, D. W., Medline, A. & Wanless, I. R. Occurrence of α1-antitrypsin deficiency in 155 patients with alcoholic liver disease. Am. J. Clin. Pathol. 82, 424-427 (1984).
38. 1-antitrysin deficiency in Japan. Am. Rev. Respir. Dis 152, 2119-2126 (1995).
39. 53αPhe) further evidence for intracellular loop-sheet polymerisation. J. Biol. Chem. 268, 15333-15335 (1993).
40. 53Phe deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerisation. J. Biol. Chem. 270, 16864-16870 (1995).
41. Millar, D. S. et al. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum. Genet. 94, 509-512 (1994).
42. 436φThr) results in nonsubstrate-like behavior and in polymerization of the molecule. J. Biol. Chem. 268, 18088-18094 (1993).
43. Elderng, E., Verpy, E., Roem, D., Meo, T. & Tosi, M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J. Biol. Chem. 270, 2579-2587 (1995).
44. 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 17, 740-743 (1993).
45. 1-antitrypsin. Nature Struct. Biol. 3, 910-911 (1996).
46. 1-antitrypsin and liver cirrhosis. J. Clin. Invest. 103, 999-1006 (1999).
47. Davis, R. L. et al. Familial encephalopathy with neuroserpin inclusion bodies (FEN1B). Am. J. Pathol. 155, 1901-1913 (1999).
48. 1-antitrypsin in hepatocytes to cause cirrhosis.
49. Bradshaw, C. B. et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease. Arch. Neurol. 58, 1429-1434 (2001).
50. Belorgey, D., Crowther, D. C., Mahadeva, R. & Lomas, D. A. Mutant neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J. Biol. Chem. 277, 17367-17373 (2002).
51. Davis, R. L. et al. Association between conformational mutations in neuroserpin and onset and seventy of dementia. Lancet 359, 2242-2247 (2002).
52. Abrahamson, M. & Grubb, A. Increased body temperature accelerates aggregation of the Leu-68oGln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc. Natl Acad. Sci. USA 91, 1416-1420 (1994).
53. Janowski, R. et al. Human cystatin C, an amyloidogenic protein dimerizes through three-dimensional domain swapping. Nature Struct Biol. 8, 316-320 (2001).
54. Staniforth, R. A. et al. Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily. EMBO J. 20, 4774-4781 (2001).
55. 2-microglobulin. Nature Struct. Biol. 9, 326-331 (2002).
56. Booth, D. R. et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793 (1997).
57. Lashuel, H. A., Wurth, C., Woo, L. & Kelly, J. W. The most pathogenic transthyretin variant, L55P forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 12, 13560-13573 (1999).
58. Eanes, E. D. & Glenner, G. G. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16, 673-677 (1968).
59. Blake, C. & Serpell, L. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous α-sheet helix. Structure 4, 989-998 (1996). Interpretation of the diffraction pattern of amyloid fibrils, with a satisfying model for their structure.
60. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739 (1997).
61. Pepys, M. B. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Phil. Trans. R. Soc. Lond. B Biol. Sci. 356, 203-210 (2001).
62. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M. & Teplow, D. B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372 (1997).
63. Goldberg, M. S. & Lansbury, P. T. J. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nature Cell Biol. 2, E115-E119 (2002).
64. Fraser, P. E. et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid β-protein. Biochemistry 31, 10716-10723 (1992).
65. Iversen, L. L., Mortishire-Smith, R. J., Pollack, S. J. & Shearman, M. S. The toxicity in vitro of β-amyloid protein. Biochem. J. 311, 1-16 (1995).
66. Polymeropoulos, M. H. et al. Mutations in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
67. Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18, 106-108 (1998).
68. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
69. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571-576 (2000).
70. Knaus, K. J. et al. Crystal structure of the human prion protein reveals a mechanism of oligomerization. Nature Struct. Biol. 8, 770-774 (2001).
71. Emmerich, J. et al. A phenylalanine 402 to leucine mutation is responsible for a stable inactive conformation of antithrombin. Thromb. Res. 76, 307-315 (1994).
72. Kelly, J. W. Mechanisms of amyloidogenesis. Nature Struct. Biol. 7, 824-826 (2000).
73. Bousset, L., Thomson, N. H., Radford, S. E. & Melki, R. The yeast prion Ure2p retains its native alpha-helical conformation upon assembly into protein fibrils in vitro. EMBO J. 21, 2903-2911 (2002).
74. Huntington, J. A. et. at al. A 2.6Å structure of a serpin polymer and implications for conformational disease. J. Mol. Biol. 293, 449-455 (1999).
75. Dunstone, M. A. et al. Cleaved antitrypsin polymers at atomic resolution. Protein Sci. 9, 417-420 (2000).
76. Iwata, N. et al. Metabolic regulation of brain Aβ by nepnysin. Science 292, 1550-1552 (2001).
77. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 505-608 (1998).
78. Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B. & Selkoe, D. J. β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. 268, 3021-3024 (1993).
79. Haass, C. et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325 (1992).
80. Shoji, M. et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258, 126-129 (1992).
81. Selkoe, D. J. Alzheimer's disease: genes, proteins and therapy. Physiol. Rev. 81, 741-766 (2001).
82. Wolfe, M. S. et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and β-secretase activity. Nature 398, 513-517 (1999).
83. Li, Y.-M. et al. Photoactivated β-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694 (2000).
84. Sinha, S. et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402, 537-540 (1999).
85. Yan, R. et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 402, 533-537 (1999).
86. Vassar, R. et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741 (1999).
87. Hussain, I. et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14, 419-427 (1999).
88. Muchowski, P. J. et al. Hsp70 and Hsp40 chaperones can inhibit self assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl Acad. Sci. USA 97, 7841-7846 (2002).
89. Perutz, M. F. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol. 6, 848-858 (1996).
90. Perutz, M. F., Finch, J. T., Berriman, J. & Lesk, A. Amyloid fibres are water, filled nanotubes. Proc. Natl Acad. Sci. USA 99, 5591-5595 (2002).
91. Soto, C. et al. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Med. 4, 822-825 (1998). Demonstration that small peptides can block the β-strand linkage of the peptide that is thought to cause Alzheimer disease and so reduce plaque formation in an animal model.
92. 1-AT deficiency. Am. J. Respir. Cell Mol. Biol. 24, 727-732 (2001).
93. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002). Elegant demonstration of the use of rational drug design to develop a drug for the treatment of the amyloidoses.
94. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916-919 (2000).
95. 1-AT)Z: a potential pharmacological strategy for prevention of liver injury and emphysema. Proc. Natl Acad. Sci. USA 97, 1796-1801 (2000).
96. Morgan, D. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000).
97. Fitton, H. L., Pike, R. N., Carrell, R. W. & Chang, W.-S. W. Mechanisms of antithrombin polymerisation and heparin activation probed by insertion of synthetic reactive loop peptides. Biol. Chem. 378, 1059-1063 (1997).
98. Chang, W.-S. W., Wardell, M. R., Lomas, D. A. & Carrell, R. W. Probing serpin reactive loop conformations by proteolytic cleavage. Biochem. J. 314, 647-653 (1996).
99. Elliott, P. R., Pei, X. Y., Dafforn, T. R. & Lomas, D. A. Topography of a 2.0Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9, 1274-1281 (2000).
100. Rubenstein, R. C. & Zeitlin, P. L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function Am. J. Respir. Crit. Care Med. 157, 484-490 (1998).